Assortment depends on the selected country

Sema

19 900 ₸
SKU: SEMA

Sema is a clinically studied peptide bioregulator used to optimize metabolic health, reduce fat mass, and improve markers directly associated with biological age and longevity. The molecule has completed the full clinical development cycle, has FDA approval, and is used in the registered medicines Ozempic®, Wegovy®, and Rybelsus®.

19 900 ₸

Description Sema:

Sema is a synthetic 31-amino-acid GLP-1 analog with two structural modifications relative to native GLP-1 and a lipid chain attached to Lys26 through a spacer, enabling pronounced albumin binding and prolonged action.

General information

PropertyValue
Peptide sequenceHis-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys[(AEEA)2-ϒ-Glu-N-(17-carboxy-1-oxoheptadecyl)]-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly
Molecular formulaC187H291N45O59
Molecular weight4113.58 g/mol
CAS number910463-68-2
SynonymsSemaglutide, NN9535, OZEMPIC, RYBELSUS, WEGOVY

Lyophilized peptides
All peptides are lyophilized, a process used to extend shelf life and preserve peptide purity and integrity during storage and transportation. This product is intended strictly for research purposes. All product information on this website is provided for educational purposes.

Product use
This product is intended strictly for research purposes. All product information presented on this website is provided for educational purposes.

Peptide purity above 99%
Verified by certified laboratories. Certificates of analysis are available before purchase.

GMR manufacturing standards
Manufactured at facilities operating in accordance with good manufacturing practices. Full product-origin traceability documentation is available.

High-standard order fulfillment
Orders placed before 12:00 Moscow time are dispatched the next day. Free standard domestic delivery is available on orders over 15,000₽ (or equivalent).

No fillers or additives
Pure active compounds only. Expert-verified composition for reliable in vitro research.